Stephan A Hahn

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7590977/publications.pdf

Version: 2024-02-01

138 papers	12,855 citations	38720 50 h-index	23514 111 g-index

144 all docs	144 docs citations	144 times ranked	14608 citing authors

#	Article	IF	Citations
1	TGFâ€beta pathway inhibition as the therapeutic acceleration of diabetic bone regeneration. Journal of Orthopaedic Research, 2022, 40, 1810-1826.	1.2	7
2	De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer. Oncogene, 2022, 41, 1507-1517.	2.6	3
3	New Therapy Options for Neuroendocrine Carcinoma of the Pancreasâ€"The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo. Cancers, 2022, 14, 2685.	1.7	3
4	Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut, 2021, 70, 743-760.	6.1	49
5	Disabling VEGF-Response of Purkinje Cells by Downregulation of KDR via miRNA-204-5p. International Journal of Molecular Sciences, 2021, 22, 2173.	1.8	3
6	Unveiling Luminescent Ir^I and Rh^I Nâ€Heterocyclic Carbene Complexes: Structure, Photophysical Specifics, and Cellular Localization in the Endoplasmic Reticulum. Chemistry - A European Journal, 2021, 27, 6783-6794.	1.7	10
7	Deficiency of myostatin protects skeletal muscle cells from ischemia reperfusion injury. Scientific Reports, 2021, 11, 12572.	1.6	9
8	Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. Genome Medicine, 2021, 13, 116.	3.6	10
9	TNF-Î±-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Nature Cancer, 2021, 2, 1185-1203.	5.7	46
10	Activation leads to a significant shift in the intracellular redox homeostasis of neutrophil-like cells. Redox Biology, 2020, 28, 101344.	3.9	15
11	Systematic Comparison of Label-Free, SILAC, and TMT Techniques to Study Early Adaption toward Inhibition of EGFR Signaling in the Colorectal Cancer Cell Line DiFi. Journal of Proteome Research, 2020, 19, 926-937.	1.8	36
12	Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells. Frontiers in Molecular Biosciences, 2020, 7, 84.	1.6	26
13	TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Cell Death Discovery, 2020, 6, 12.	2.0	30
14	Characterization of a dual <scp>BET</scp>/<scp>HDAC</scp> inhibitor for treatment of pancreatic ductal adenocarcinoma. International Journal of Cancer, 2020, 147, 2847-2861.	2.3	34
15	Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study.. Journal of Clinical Oncology, 2020, 38, e16750-e16750.	0.8	5
16	Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation With Implications for Adoptive T-Cell Therapy. Frontiers in Oncology, 2020, 10, 568056.	1.3	11
17	Abstract 1873: Drivers of secondary resistance to anti-EGFR therapy in metastatic colorectal cancer. , 2020, , .		0
18	Alterations in pectoralis muscle cell characteristics after radiation of the human breast in situ. Journal of Radiation Research, 2019, 60, 825-830.	0.8	11

#	Article	IF	Citations
19	Deregulated miR-29b-3p Correlates with Tissue-Specific Activation of Intrinsic Apoptosis in An Animal Model of Amyotrophic Lateral Sclerosis. Cells, 2019, 8, 1077.	1.8	25
20	Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer. Cancer Research, 2019, 79, 2367-2378.	0.4	60
21	MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS. Journal of Neuro-Oncology, 2018, 137, 463-468.	1.4	26
22	Exploring the efficacy and cellular uptake of sorafenib in colon cancer cells by Raman micro-spectroscopy. Analyst, The, 2018, 143, 6069-6078.	1.7	13
23	Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level. Scientific Reports, 2018, 8, 15278.	1.6	26
24	Unveiling of miRNA Expression Patterns in Purkinje Cells During Development. Cerebellum, 2017, 16, 376-387.	1.4	19
25	Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo. BMC Cancer, 2017, 17, 216.	1.1	11
26	Bloodâ€based detection of <scp>RAS</scp> mutations to guide antiâ€<scp>EGFR</scp> therapy in colorectal cancer patients: concordance of results from circulating tumor <scp>DNA</scp> and tissueâ€based <scp>RAS</scp> testing. Molecular Oncology, 2017, 11, 208-219.	2.1	125
27	Asymmetric rhenium tricarbonyl complexes show superior luminescence properties in live cell imaging. Chemical Communications, 2017, 53, 905-908.	2.2	36
28	A genetic roadmap of pancreatic cancer: still evolving. Gut, 2017, 66, 2170-2178.	6.1	41
29	Activation of odorant receptor in colorectal cancer cells leads to inhibition of cell proliferation and apoptosis. PLoS ONE, 2017, 12, e0172491.	1.1	60
30	Circular RNA expression in cutaneous squamous cell carcinoma. Journal of Dermatological Science, 2016, 83, 210-218.	1.0	124
31	Expression profiles of long noncoding RNAs in cutaneous squamous cell carcinoma. Epigenomics, 2016, 8, 501-518.	1.0	26
32	Circular RNA expression in basal cell carcinoma. Epigenomics, 2016, 8, 619-632.	1.0	85
33	A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut, 2016, 65, 647-657.	6.1	57
34	Nuclear spheres modulate the expression of BEST1 and GADD45G. Cellular Signalling, 2016, 28, 100-109.	1.7	5
35	Long-noncoding RNAs in basal cell carcinoma. Tumor Biology, 2016, 37, 10595-10608.	0.8	35
36	Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 795-805.	1.2	34

#	Article	IF	Citations
37	Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma. Neuro-Oncology, 2016, 18, 361-367.	0.6	42
38	The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut, 2015, 64, 1936-1948.	6.1	123
39	Label-Free Raman Spectroscopic Imaging Monitors the Integral Physiologically Relevant Drug Responses in Cancer Cells. Analytical Chemistry, 2015, 87, 7297-7304.	3.2	60
40	MiR-93 Controls Adiposity via Inhibition of Sirt7 and Tbx3. Cell Reports, 2015, 12, 1594-1605.	2.9	95
41	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1163-1171.	15.2	349
42	In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging. Analytical and Bioanalytical Chemistry, 2015, 407, 8321-8331.	1.9	29
43	The pancreatic expression database: recent extensions and updates. Nucleic Acids Research, 2014, 42, D944-D949.	6.5	28
44	Quantitative RT-PCR Specific for Precursor and Mature miRNAs. Methods in Molecular Biology, 2014, 1095, 121-134.	0.4	7
45	New insights in the composition of extracellular vesicles from pancreatic cancer cells: implications for biomarkers and functions. Proteome Science, 2014, 12, 50.	0.7	48
46	Analysis of U2 Small Nuclear RNA Fragments in the Bile Differentiates Cholangiocarcinoma from Primary Sclerosing Cholangitis and Other Benign Biliary Disorders. Digestive Diseases and Sciences, 2014, 59, 1436-1441.	1.1	18
47	A MicroRNA-Based Test Improves Endoscopic Ultrasoundâ€“Guided Cytologic Diagnosis of Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2014, 12, 1717-1723.	2.4	34
48	Induction of pancreatic cancer cell migration by an autocrine epidermal growth factor receptor activation. Experimental Cell Research, 2014, 326, 307-314.	1.2	15
49	Lentiviral Overexpression of miRNAs. Methods in Molecular Biology, 2014, 1095, 177-190.	0.4	11
50	Circulating U2 Small Nuclear RNA Fragments as a Novel Diagnostic Tool for Patients with Epithelial Ovarian Cancer. Clinical Chemistry, 2014, 60, 206-213.	1.5	59
51	Suppression of soluble adenylyl cyclase protects smooth muscle cells against oxidative stress-induced apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 1069-1079.	2.2	18
52	Automated Identification of Subcellular Organelles by Coherent Anti-Stokes Raman Scattering. Biophysical Journal, 2014, 106, 1910-1920.	0.2	43
53	A Soluble Form of the Giant Cadherin Fat1 Is Released from Pancreatic Cancer Cells by ADAM10 Mediated Ectodomain Shedding. PLoS ONE, 2014, 9, e90461.	1.1	24
54	U2 Small Nuclear RNA as a Biomarker in Cancer. , 2014, , 1-15.		0

#	Article	IF	Citations
55	Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell and Tissue Research, 2013, 351, 85-98.	1.5	137
56	Norepinephrine inhibits the migratory activity of pancreatic cancer cells. Experimental Cell Research, 2013, 319, 1744-1758.	1.2	24
57	Small molecule inhibition of the KRASâ€“PDEÎ´ interaction impairs oncogenic KRAS signalling. Nature, 2013, 497, 638-642.	13.7	551
58	Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut, 2013, 62, 1034-1043.	6.1	67
59	Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. International Journal of Cancer, 2013, 132, E48-57.	2.3	126
60	EU Pancreas: An Integrated European Platform for Pancreas Cancer Research - from Basic Science to Clinical and Public Health Interventions for a Rare Disease. Public Health Genomics, 2013, 16, 305-312.	0.6	2
61	Keratin23 (KRT23) Knockdown Decreases Proliferation and Affects the DNA Damage Response of Colon Cancer Cells. PLoS ONE, 2013, 8, e73593.	1.1	35
62	Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. PLoS ONE, 2013, 8, e66371.	1.1	33
63	Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro-Oncology, 2012, 14, 29-33.	0.6	174
64	Expression of microRNAs in basal cell carcinoma. British Journal of Dermatology, 2012, 167, 847-855.	1.4	172
65	MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. Journal of Neuro-Oncology, 2012, 109, 239-244.	1.4	67
66	Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma. Journal of Dermatological Science, 2012, 68, 119-126.	1.0	98
67	Robust adaption algorithm for effective and safe sonoporation therapy. Biomedizinische Technik, 2012, 57, .	0.9	0
68	MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis, 2012, 33, 732-739.	1.3	160
69	Global microRNA expression profiling of microdissected tissues identifies miRâ€135b as a novel biomarker for pancreatic ductal adenocarcinoma. International Journal of Cancer, 2012, 131, E86-95.	2.3	90
70	Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. International Journal of Cancer, 2012, 131, E371-81.	2.3	31
71	Microcapsules: Reverse Sonoporation and Long-lasting, Safe Contrast. Acoustical Imaging, 2012, , 81-90.	0.2	4
72	Abstract 4132:MicroRNA-1246 as a novel candidate for a blood-based biomarker in ovarian cancer patients. , 2012, , .		1

#	Article	IF	Citations
73	Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood, 2011, 117, 3140-3146.	0.6	284
74	Keratin 23, a novel DPC4/Smad4 target gene which binds 14-3-3Îµ. BMC Cancer, 2011, 11, 137.	1.1	28
75	A Novel Organometallic Re^I Complex with Favourable Properties for Bioimaging and Applicability in Solidâ€Phase Peptide Synthesis. ChemBioChem, 2011, 12, 371-376.	1.3	59
76	MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. Laboratory Investigation, 2011, 91, 1472-1479.	1.7	106
77	The Pancreatic Expression database: 2011 update. Nucleic Acids Research, 2011, 39, D1023-D1028.	6.5	29
78	Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells. British Journal of Cancer, 2011, 105, 552-561.	2.9	106
79	Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Familial Cancer, 2010, 9, 335-343.	0.9	44
80	Gene expression analysis of cell death induction by Taurolidine in different malignant cell lines. BMC Cancer, 2010, 10, 595.	1.1	14
81	Clinical and genetic analysis of 18 pancreatic carcinoma/melanomaâ€prone families. Clinical Genetics, 2010, 77, 333-341.	1.0	25
82	Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines. Journal of Experimental and Clinical Cancer Research, 2010, 29, 21.	3.5	18
83	Abstract 4678: KIAA1199 depletion targets the wnt/beta catenin signaling pathway and impairs migration and proliferation of human colon cancer cells. , 2010, , .		1
84	Detection of Clonal T Cells in the Circulation of Patients With Nephrogenic Systemic Fibrosis. Archives of Dermatology, 2009, 145, 1164-9.	1.7	10
85	Clonal T-cell populations are frequent in the skin and blood of patients with systemic sclerosis. British Journal of Dermatology, 2009, 161, 785-790.	1.4	15
86	Analysis of the Pancreatic Tumor Progression by a Quantitative Proteomic Approach and Immunhistochemical Validation. Journal of Proteome Research, 2009, 8, 1647-1656.	1.8	67
87	Pancreatic Intraepithelial Neoplasia Revisited and Updated. Pancreatology, 2009, 9, 45-54.	0.5	102
88	A Web-Based Platform for Mining Pancreatic Expression Datasets. Pancreatology, 2009, 9, 340-343.	0.5	7
89	Manual Microdissection Combined with Antisense RNAâ€“LongSAGE for the Analysis of Limited Cell Numbers. Methods in Molecular Biology, 2009, 576, 135-154.	0.4	3
90	Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. International Journal of Colorectal Disease, 2008, 23, 1033-1039.	1.0	64

#	Article	IF	Citations
91	Divergent mechanisms underlie Smad4-mediated positive regulation of the three genes encoding the basement membrane component laminin-332 (laminin-5). BMC Cancer, 2008, 8, 215.	1.1	14
92	Application of Fluorescence Dye Saturation Labeling for Differential Proteome Analysis of 1,000 Microdissected Cells from Pancreatic Ductal Adenocarcinoma Precursor Lesions. Methods in Molecular Biology, 2008, 425, 1-14.	0.4	6
93	Analysis of MicroRNAs in Pancreatic Fine-Needle Aspirates Can Classify Benign and Malignant Tissues. Clinical Chemistry, 2008, 54, 1716-1724.	1.5	194
94	Monitoring and modeling of microbubble behavior during ultrasound mediated transfection of cell monolayers. , 2008, , .		3
95	MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene, 2007, 26, 4442-4452.	2.6	617
96	High-level inducible Smad4-reexpression in the cervical cancer cell line C4-II is associated with a gene expression profile that predicts a preferential role of Smad4 in extracellular matrix composition. BMC Cancer, 2007, 7, 209.	1.1	8
97	Discarding duplicate ditags in LongSAGE analysis may introduce significant error. BMC Bioinformatics, 2007, 8, 92.	1.2	8
98	Pancreatic Expression database: a generic model for the organization, integration and mining of complex cancer datasets. BMC Genomics, 2007, 8, 439.	1.2	38
99	Low Frequency of CHEK2 Mutations in Familial Pancreatic Cancer. Familial Cancer, 2006, 5, 305-308.	0.9	32
100	Differential proteome analysis of colon carcinoma cell line SW480 after reconstitution of the tumour suppressor Smad4. Analytical and Bioanalytical Chemistry, 2006, 386, 1603-1612.	1.9	6
101	Anticipation in familial pancreatic cancer. Gut, 2006, 55, 252-258.	6.1	112
102	Evaluation of the 4q32-34 Locus in European Familial Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1948-1955.	1.1	50
103	Smad4 deficiency in cervical carcinoma cells. Oncogene, 2005, 24, 810-819.	2.6	35
104	Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene, 2005, 24, 6626-6636.	2.6	174
105	RNASEL germline variants are associated with pancreatic cancer. International Journal of Cancer, 2005, 117, 718-722.	2.3	39
106	Gibt es Perspektiven zur Frï¿½herkennung des Pankreaskarzinoms?. Der Pathologe, 2005, 26, 11-11.	0.7	1
107	Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. Proteomics, 2005, 5, 2665-2679.	1.3	127
108	Genetics of Hereditary Pancreatic Carcinoma. Clinics in Laboratory Medicine, 2005, 25, 117-133.	0.7	3

#	Article	IF	Citations
109	HNPCC-associated small bowel cancer: Clinical and molecular characteristics. Gastroenterology, 2005, 128, 590-599.	0.6	186
110	aRNA-longSAGE: a new approach to generate SAGE libraries from microdissected cells. Nucleic Acids Research, 2004, 32, e131-e131.	6.5	32
111	Where and When Does Pancreatic Carcinoma Start?. Medizinische Klinik, 2004, 99, 191-195.	0.5	8
112	Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by aâ€œsecretomeâ€•analysis. Proteomics, 2004, 4, 1324-1334.	1.3	41
113	HNPCC: Six new pathogenic mutations. BMC Medical Genetics, 2004, 5, 16.	2.1	3
114	Prevalence of familial pancreatic cancer in Germany. International Journal of Cancer, 2004, 110, 902-906.	2.3	78
115	Genetics of hereditary pancreatic carcinoma. Gastroenterology Clinics of North America, 2004, 33, 919-934.	1.0	4
116	The NOD2 3020insC Mutation and The Risk of Familial Pancreatic Cancer?. Hereditary Cancer in Clinical Practice, 2004, 2, 149.	0.6	16
117	Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine. Cancer, 2003, 98, 1774-1775.	2.0	2
118	BRCA2 Germline Mutations in Familial Pancreatic Carcinoma. Journal of the National Cancer Institute, 2003, 95, 214-221.	3.0	457
119	CDKN2A Germline Mutations in Familial Pancreatic Cancer. Annals of Surgery, 2002, 236, 730-737.	2.1	157
120	German National Case Collection of Familial Pancreatic Cancer â€“ Clinical-Genetic Analysis of the First 21 Families. Oncology Research and Treatment, 2002, 25, 262-266.	0.8	21
121	Molecular pathogenesis of pancreatic cancer. Hematology/Oncology Clinics of North America, 2002, 16, 17-35.	0.9	11
122	SMIF, a Smad4-interacting protein that functions as a co-activator in TGFÎ² signalling. Nature Cell Biology, 2002, 4, 181-190.	4.6	82
123	Pankreaskarzinom. , 2002, , 187-206.		0
124	Allelic Loss Is Often the First Hit in the Biallelic Inactivation of the p53 and DPC4 Genes During Pancreatic Carcinogenesis. American Journal of Pathology, 2001, 158, 1677-1683.	1.9	217
125	Update of Familial Pancreatic Cancer in Germany. Pancreatology, 2001, 1, 510-516.	0.5	35
126	Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 9624-9629.	3.3	236

#	Article	IF	Citations
127	DPC4/Smad4 mediated tumor suppression in pancreatic cancer cells through suppression of angiogenesis. Gastroenterology, 2000, 118, A50.	0.6	1
128	Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene, 1999, 18, 2367-2371.	2.6	118
129	DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression. Oncogene, 1999, 18, 3152-3158.	2.6	73
130	The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouseâ€‰embryo. Genes and Development, 1998, 12, 107-119.	2.7	448
131	Recent Discoveries in Cancer Genetics of Exocrine Pancreatic Neoplasia. Digestion, 1998, 59, 493-501.	1.2	51
132	DPC4 gene mutation in colitis associated neoplasia.. Gut, 1997, 40, 120-122.	6.1	48
133	DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1. Science, 1996, 271, 350-353.	6.0	2,180
134	Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nature Genetics, 1996, 13, 343-346.	9.4	580
135	Molecular Genetics of Exocrine Pancreatic Neoplasms. Surgical Clinics of North America, 1995, 75, 857-869.	0.5	58
136	Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 5950-5954.	3.3	155
137	Molecular genetics of pancreatic carcinoma. Cancer Genetics and Cytogenetics, 1995, 84, 130.	1.0	2
138	Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genetics, 1994, 8, 27-32.	9.4	1,063